Header cover image

Australian (ASX) Biotech Industry Analysis

UpdatedFeb 21, 2024
DataAggregated Company Financials
Companies33
  • 7D0.01%
  • 3M9.1%
  • 1Y-5.5%
  • YTD-1.8%

Over the last 7 days, the Biotech industry has remained flat, although notably Imugene gained 4.8%. As for the longer term, the industry has declined 5.5% in the last year. Looking forward, earnings are forecast to grow by 17% annually.

Industry Valuation and Performance

Has the Australian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 21 Feb 2024AU$143.3bAU$22.3bAU$3.3b31.4x43.6x6.4x
Fri, 19 Jan 2024AU$144.0bAU$20.9bAU$2.8b33.1x51.9x6.9x
Sun, 17 Dec 2023AU$141.5bAU$20.5bAU$2.7b34.1x52.3x6.9x
Tue, 14 Nov 2023AU$128.5bAU$21.5bAU$2.9b30.4x44.7x6x
Thu, 12 Oct 2023AU$130.3bAU$21.4bAU$2.8b30.8x46.4x6.1x
Sat, 09 Sep 2023AU$138.6bAU$21.5bAU$2.8b32.7x49.2x6.4x
Mon, 07 Aug 2023AU$136.2bAU$18.3bAU$2.4b36.3x57.4x7.4x
Wed, 05 Jul 2023AU$142.5bAU$18.0bAU$2.3b38.2x61.3x7.9x
Fri, 02 Jun 2023AU$158.5bAU$18.4bAU$2.4b40x66.2x8.6x
Sun, 30 Apr 2023AU$153.8bAU$18.2bAU$2.3b41.6x65.5x8.5x
Tue, 28 Mar 2023AU$147.2bAU$18.1bAU$2.3b39.2x62.8x8.1x
Thu, 23 Feb 2023AU$150.5bAU$17.5bAU$2.3b50.8x65.2x8.6x
Sat, 21 Jan 2023AU$152.7bAU$15.6bAU$2.5b53.6x61.9x9.8x
Mon, 19 Dec 2022AU$149.0bAU$16.1bAU$2.6b46.8x58x9.3x
Wed, 16 Nov 2022AU$148.8bAU$16.0bAU$2.5b43.7x58.4x9.3x
Fri, 14 Oct 2022AU$140.9bAU$17.1bAU$2.8b39.4x51.1x8.2x
Sun, 11 Sep 2022AU$152.0bAU$15.7bAU$2.5b46.9x60.8x9.7x
Tue, 09 Aug 2022AU$151.0bAU$15.6bAU$2.8b41x53.5x9.7x
Thu, 07 Jul 2022AU$144.6bAU$15.9bAU$2.9b36.7x50.2x9.1x
Sat, 04 Jun 2022AU$136.0bAU$14.9bAU$2.7b35.8x50.9x9.1x
Mon, 02 May 2022AU$138.6bAU$15.2bAU$2.8b37.1x50.1x9.2x
Wed, 30 Mar 2022AU$135.5bAU$14.4bAU$2.6b40x52x9.4x
Fri, 25 Feb 2022AU$135.5bAU$14.9bAU$2.7b37.4x50.9x9.1x
Sun, 23 Jan 2022AU$137.3bAU$14.5bAU$2.8b38.4x49.6x9.4x
Tue, 21 Dec 2021AU$142.5bAU$14.6bAU$2.8b39.5x51.1x9.7x
Thu, 18 Nov 2021AU$153.7bAU$14.3bAU$2.7b43.4x56.7x10.7x
Sat, 16 Oct 2021AU$147.8bAU$14.1bAU$2.7b42.3x55.5x10.5x
Mon, 13 Sep 2021AU$150.2bAU$14.0bAU$2.6b43.5x57.2x10.8x
Wed, 11 Aug 2021AU$144.3bAU$14.0bAU$2.6b42.1x54.9x10.3x
Sun, 06 Jun 2021AU$142.6bAU$13.5bAU$2.8b39.9x50.3x10.5x
Wed, 10 Mar 2021AU$128.5bAU$13.1bAU$3.0b34.6x43x9.8x
Price to Earnings Ratio

43x


Total Market Cap: AU$128.5bTotal Earnings: AU$3.0bTotal Revenue: AU$13.1bTotal Market Cap vs Earnings and Revenue0%0%0%
Australian Biotech Industry Price to Earnings3Y Average 54.1x202220232024
Current Industry PE
  • Investors are pessimistic on the Australian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 43.6x which is lower than its 3-year average PE of 54.1x.
  • The 3-year average PS ratio of 8.9x is higher than the industry's current PS ratio of 6.4x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 3.2% per year over the last three years.
  • Revenues for these companies have grown 19% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Australian Healthcare industry?

AU Market0.81%
Healthcare-1.32%
Biotech0.013%
Biotech0.013%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CSL CSLAU$284.271.5%
+AU$2.0b
-3.9%PE36.4x
CUV Clinuvel PharmaceuticalsAU$16.293.8%
+AU$29.6m
-30.9%PE26.7x
MSB MesoblastAU$0.295.5%
+AU$15.2m
-69.6%PS25.7x
OPT OptheaAU$0.593.5%
+AU$13.3m
-35.9%PS665.2x
PYC PYC TherapeuticsAU$0.0792.6%
+AU$7.5m
12.9%PS18.7x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

OPT

AU$0.59

Opthea

7D

4.4%

1Y

-34.6%

CUV

AU$16.33

Clinuvel Pharmaceuticals

7D

2.6%

1Y

-31.3%

CSL

AU$282.28

CSL

7D

0.01%

1Y

-5.4%

ATH

AU$0.004

Alterity Therapeutics

7D

-11.1%

1Y

-55.6%

ARX

AU$0.59

Aroa Biosurgery

7D

2.6%

1Y

-46.8%

PAR

AU$0.35

Paradigm Biopharmaceuticals

7D

-7.9%

1Y

-76.1%

TLX

AU$11.32

Telix Pharmaceuticals

7D

-1.6%

1Y

79.7%

MSB

AU$0.29

Mesoblast

7D

3.6%

1Y

-69.9%

PTX

AU$0.047

Prescient Therapeutics

7D

-7.8%

1Y

-50.5%

KZA

AU$0.08

Kazia Therapeutics

7D

-27.3%

1Y

-17.5%

IMM

AU$0.35

Immutep

7D

-2.7%

1Y

39.2%

ACW

AU$0.037

Actinogen Medical

7D

-5.1%

1Y

-54.3%

PYC

AU$0.085

PYC Therapeutics

7D

6.3%

1Y

19.7%

IMU

AU$0.11

Imugene

7D

4.8%

1Y

-18.5%